MARK2 and glioblastoma: Chromosome 1p and 19q codeletion, mutations in  ATRX, telomerase reverse transcriptase (TERT) promoter, tumor protein p53 (TP53), and B-raf proto-oncogene as well as serine/threonine kinase (BRAF) V600E mutation are also supportive for GBM diagnosis[13].